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Background: Cystic Fibrosis (CF) is one of the most common autosomal recessive genetic disorders, with the majority of patients born to couples
unaware of their carrier status. Carrier screenings might help reducing the incidence of CF.
Methods: We used a semi-automated reverse-dot blot assay identifying the 47 most common CFTR gene mutations followed by DGGE/dHPLC
analysis.
Results: Results of a 10-year (1996–2006) CF carrier screening on 57,999 individuals with no prior family history of CF are reported. Of these,
25,104 were couples and 7791 singles, with 77.9% from the Italian Veneto region. CFTR mutations were found in 1879 carriers (frequency 1/31),
with ΔF508 being the most common (42.6%). Subjects undergoing medically assisted reproduction (MAR) had significantly (pb0.0001) higher
CF carrier frequency (1/22 vs 1/32) compared to non-MAR subjects.
Conclusions: If coupled to counselling programmes, CF carrier screening tests might help reducing the CF incidence.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Screening; CF carrier; CFTR; Reverse dot-blot1. Introduction
Although newly developed therapies have increased life
expectancy to late 30s, Cystic Fibrosis (CF) remains a serious
and very often lethal disorder. The leading cause of morbidity
and mortality is the progressive decline in pulmonary function
[1] and approximately 85% of CF patients develop insufficiency
of the exocrine pancreas. Nearly all CF males are infertile
because of congenital bilateral absence of the vas deferens
(CBAVD) [2,3]. No definitive cures are available, even if
experimental treatments based on gene therapy [4] and
pharmacological approaches [5] aimed at modulating the⁎ Corresponding author. Department of Paediatrics, University of Padova, Via
Giustiniani 3, 35128 Padova, Italy. Tel.: +39 049 8213505; fax: +39 049
8213502.
E-mail address: scarpa@pediatria.unipd.it (M. Scarpa).
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.10.003residual activity of mutated Cystic Fibrosis Transmembrane
conductance Regulator (CFTR) channels are currently being
evaluated.
CF has a high incidence among the Caucasian population
(1/2500) and more than 1500 different mutations have been
identified. The risk of CF mutation carrier status varies by
ethnicity, with the highest in people of Northern European
ancestry (1/25) and of Ashkenazi Jewish descendent (1/29). As
typical of recessive disorders, the majority of affected
individuals are born to couples not knowing to be at risk.
Heterozygotes are in fact phenotypically normal and most
unaware of their carrier status. In 1989, CFTR gene cloning [6]
opened up the possibility of identifying subjects at risk through
DNA testing. Because of the high incidence of CFTRmutations,
in 2001, the American College of Medical Genetics and the
American College of Obstetricians and Gynecologists published
guidelines [7,8] for population-based CF screening and
recommended CF carrier screening to be offered to couples in
high-risk groups contemplating pregnancy. Screening tests ared by Elsevier B.V. All rights reserved.
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testing platforms capable of automated, high-throughput and
accurate identification of CFTR mutations have been developed.
Identification of novel (usually “mild”) mutations and/or
polymorphisms together with the development of sophisticated
clinical tests have raised the issue of “atypical” or “non-
classical” forms of CF. Subjects with “atypical” CF may present
with single organ involvement such as CBAVD, disseminated
bronchiectasis, acute or chronic pancreatitis. The idea that “two
mutations within the CFTR gene would mean CF and normal
genes would exclude the diagnosis” has therefore not worked
out that simply. The presence of mild mutations, polymorph-
isms and modifying genes is therefore widening the range of
clinical phenotypes that previously would have never been con-
sidered within the CF spectrum thus posing important dilemmas
to clinicians [9].
In this study we report the results of a 10-year CF-carrier
screening program on 57,999 subjectswith no prior family history
of CF. To our knowledge this is the most comprehensive
screening for CF carriers in the Italian population, thus providing
large-scale data on the frequency of CFTR mutations and raising
important issues related to current genetic counselling practises.2. Materials and methods
2.1. Subjects
The report presents the data gained from 59,782 adults
enrolled in the CF carrier-screening program carried out at the
Paediatrics Department at the University of Padova over a 10-
year period (from 1996 to 2006). As 1783 subjects had a family
history of CF, only 57,999 individuals were considered for CF
carrier frequency evaluation (28,026 males and 29,973 females,
ranging from 20 to 50 years of age, with 50,208 of whom
belonging to 25,104 couples and the remaining 7791 being
singles). All subjects were in good health, showed no clinical
evidence of CF and had no relatives with CF. Individuals
screened were informed about our CF carrier screening
programme by their GPs (approximately 30%), friends/relatives
previously screened and, importantly, public awareness raised
by the Paediatrics Department through conferences and leaflets.
For all of them knowing the risk to conceive a child with CF
was the main reason to undertake the screening test.
Within this population, separate data were gathered from a
sub-group of subjects (n=5196) undergoing medically assisted
reproduction (MAR) and being advised to carry out a CFTR
mutation screening test by gynaeconologists or centres for
MAR. Subjects reporting CF familiarity (n=8) were not
included in this sub-group.
Before collection of blood specimens, subjects were asked to
fill out an informed consent form (approved by the Local Ethic
Committee of the Paediatrics Department) providing informa-
tion about CF, carrier-screening tests and the risks associated
when mutations are identified. The costs associated with the
screening tests are reimbursed by the Veneto region, with a
small fee (“ticket”) being paid by the subjects analysed.2.2. Selection of mutations to be analysed
The choice of mutations to include in the screening test was
made on the basis of databases [10–12] reporting the frequency of
CFTR mutations in northern and southern Italy. Briefly, in
northern Italy, the 15 most common mutations allowed a
projected allele detection of 87.1%, with an estimated rate of
detection of twoCFTRmutations of 75.9% [10]. In southern Italy,
the 13most commonmutations gave values of 85.7% and 73.4%,
respectively, for the two parameters above mentioned [11,12].
Forty-seven different CFTR mutations/gene alterations were
chosen and analysed: ΔF508, G85E, 541delC, D110H, R117H,
621+1G→T, 711+5G→A, R334W, R334Q, T338I, R347H,
R347P, R352Q, S466X, ΔI507, E527G, 1717-1G→A, 1717-
8G→A,G542X, S549N, S549RA→C,G551D,Q552X, R553X,
D579G, 1874insT, E585X, 1898+3A→G, 2183AA→G,
2184delA, R709X, 2789+5G→A, 3132delTG, 3199del6,
3272-26A→G, L1077P, L1065P, R1066H, M1101K, D1152H,
R1158X, R1162X, 3849+10KbC→T, G1244E, W1282X,
N1303K and 4016insT.
2.3. CFTR mutation analysis
CFTR gene mutations were identified through a semi-
automated procedure based on a single multiplex PCR amplifi-
cation followed by allele-specific oligonucleotide reverse-dot blot
(RDB) as previously described [13]. Briefly, oligonucleotide
probes complementary to the CFTR mutations listed above and
their corresponding normal alleles were bound to a filter
membrane to which biotin-labelled PCR products amplified
from the subjects' DNA were subsequently hybridized.
DNA was extracted from 200 μl of peripheral blood
lymphocytes using a Biorobot Multiprobe® II Packard (Perkin
Elmer, Waltham, MA, USA) and a QIAamp® 96 DNA Blood
Biorobot Qiagen kit (Qiagen GmbH, Hilden, Germany). Each
DNA sample underwent four multiplex PCR amplifications:
multiplex (A) for amplification of exons 7, 10, 13 and 19; (B) for
exons 5, 11, 12 and 20; (C) for exons 3, 4, 14b and 21; (D) for
exons 9, 17a, 17b, 18 and intron 19. Sequences of primers used
for CFTR exon/intron amplifications were previously described
[14]. Amplification of 400 ng genomic DNA was carried out
using a PCR reaction mixture (30 μl) containing the following:
6.7 mMMgCl2, 1X buffer [67 mM Tris–HCl, pH 8,8, 1.66 mM
(NH4)SO4, 0.1% Tween-20], 1.5U of Taq polymerase (Poly-
med), 5 μM Biotin-16-dUTP, 100 μM of each dNTP and
primers (1–2nM each). PCR amplifications were performed
with an initial denaturation step at 95 °C for 5 min, followed by
35cycles of denaturation (30 s at 94 °C), annealing (45 s at
62 °C) and extension (45 s at 72 °C), followed by a final
extension step of 7 min at 72 °C.
To avoid false-negative results, in couples with one of the
two partners carrying a CFTR mutation, DNA from the
“negative” subject was further analysed by scanning all 27
exons and their intronic boundaries through Denaturing
Gradient Gel Electrophoresis (DGGE) (Bio-Rad, Hercules,
CA, USA) and/or denaturing High Performance Liquid phase
Cromatography (dHPLC) (Transgenomic, Omaha, NE, USA)
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reported previously [15,16]. Abnormal DGGE and/or dHPLC
patterns were followed by automated DNA sequencing using an
ABI PRISM 3100 sequencer (Applied Biosystems, Foster City,
CA, USA).
2.4. Statistical analysis
Data are presented as counts and percentages. Odds-ratio and
95% confidence interval was used to estimate the risk of CF
mutations of MAR subjects compared to non MAR subjects and
the p value is obtained with the chi-square test.
3. Results
3.1. CF carrier testing in the general adult population
During the decade 1996–2006, a total of 59,782 subjects
were assessed for their CF carrier status. Subjects having a
family history of CF (n=1783) were excluded from the study,
thus restricting the number of individuals to be considered for
CF carrier frequency evaluation to 57,999. Among all the
individuals screened, we identified 1879 CF carriers with an
overall frequency in the general population of 1:31 (3.23%).
When individuals with a family history of CF were included
(541 CF carriers were identified out of 1783 analysed), the
frequency of carriers increased from 1:31 to 1:25. Since 77.9%
of the subjects analysed were from the Veneto region and only
subjects with no previous history of CF were included in this
study, the 1:31 frequency value could be regarded as the
potential a priori risk for CF carrier status for Italian north-Fig. 1. Algorithm for CF carrier screening test. The strategy used in our study involv
and a “failsafe” protocol to discriminate potential false negatives. In couples with one
analysed through DGGE and/or dHPLC.eastern populations. Distribution of CF mutation frequencies is
indicated in Table 1. As expected, ΔF508 was the most
common mutation (42.6%).
In addition, 10 compound heterozygotes were identified and
mutations are indicated in Table 2a. Interestingly 7 out of 10
subjects, despite not showing classical symptoms of CF, were
found to have infertility problems, with 5 of them having
CBAVD. For many of these subjects mutations were identified
following DGGE and/or dHPLC analysis, and not through the
RDB-based test, as gene alterations are “rare”/uncommon
[A238V, R352W, S42F, (V201M, D1270N & R74W) and
L206W] or because they have never been identified before
[D372E (1251T→G) and L1414S (4373T→C)]. Our findings
confirm what previously shown by other studies with regard to
mild CFTR mutations/polymorphisms being associated with
male infertility. For example, the compound heterozygote
ΔF508/R117H, previously reported to occur commonly in
CBAVD and infertile patients [20,21], was also a frequent
genotype in our study (Table 2b).
3.2. Frequency of CFTR mutations in couples from the general
population
A total of 25,104 couples with no family history of CF
contacted our centre in order to have a CFTRmutation screening
carried out. Fig. 1 shows the flow of analyses undertaken by
every couple entering our screening test, with 1st- (47 mutation-
based RDB assay) and 2nd-level (dHPLC and/or DGGE)
analyses. For 24,181 of these couples, results from RDB were
negative and any further investigation terminated. In couples
with one of the two partners carrying a mutation (identifiedes assays for multiple CFTR mutation detection (47 mutation based-RDB assay)
of the two partners carrying a CFTR mutation, the “negative” subject is further
Table 1
Frequency (%) of CF mutations in carriers from the general adult population
(n=1879) and from the population (n=236) enrolled for medically assisted
reproduction (MAR).
CF mutation General adult population MAR population
n=1879 n=236
ΔF508 42.6 45.7
2183AA→G 5.9 5.9
R1162X 5.7 8.2
N1303K 5.4 5.9
G542X 4.2 3.7
D1152H 3.9 5.0
R553X 3.7 3.1
R117H 3.3 1.8
711+5G→A 2.8 4.1
Q552X 2.8 0.4
2789+5G→A 2.2 3.1
1717-1G→A 2.6 2.8
E527G 2.4 –
G85E 2.4 0.9
R334Q 0.9 0.4
W1282X 0.7 0.9
R334W 0.6 –
1898+3A→G 0.5 0.4
R1158X 0.4 –
R1066H 0.4 0.4
T338I 0.4 1.8
3849+10Kb C→T 0.4 1.3
3272-26 A→G – 0.9
3132delTG – 0.9
3659 del C – 0.4
4016 ins T – 0.4
1717-8G→A – 0.4
R347H – 0.4
ΔI507 – 0.4
R1070Q – 0.4
Other (16) 5.4 –
Table 2b
List of CFTR compound heterozygotes in the population enrolled for medically
assisted reproduction.
Mutation Disorder Gender Age (years) Notes and refs
ΔF508/R117H M 47 (C) [20,21]
ΔF508/R117H F 36 (C) [20,21]
ΔF508/R117H M 43 (C) [20,21]
G542X/D1152H M 40 (C)
R1162X/2789+5G→A CBAVD M 44 (C)
R117H/2789+5G→A CBAVD M 42 (C)
N1303K/D110H CBAVD M 32 (C)
N1303K/D1152H M 40 (C)
2789+5G→A/R1066H M 40 (C)
Abbreviations: CBAVD: Congenital Bilateral Absence of the Vas Deference;
M: Male; F: Female.
Notes to Tables: (A) CFTR mutations A238V, R352W, 4006-19del3, S42F,
D372E (1251T→G), L1414S (4373T→C), (V201M, D1270N & R74W) and
L206W are not included in the RDB-based screening. Evaluation was carried
out through DGGE and/or dHPLC.
(B) D372E (1251T→G) and L1414S (4373T→C) are CFTR mutation that have
never been described before (see Table 4).
(C) Compound heterozygote subjects from population enrolled for medical
assisted reproduction.
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through DGGE and/or dHPLC in order to discriminate potential
false negatives. Overall, out of all the couples screened
(n=25,104), 815 had one of the two partners carrying a CFTR
mutation and in 108 both partners were CF carriers, thus giving a
1/232 frequency of couples with both partners being hetero-
zygotes in the general population. Couples with both partnersTable 2a
List of CFTR compound heterozygotes in the adult general population.
Mutation Health
status
Disorder Gender Age
(years)
Notes and
refs
ΔF508/A238V Infertile CBAVD M 36 (A)
ΔF508/R352W Infertile CBAVD M 45 (A)
R553X/R334Q M 38
ΔF508/R347H M 53 [17]
S42F/D372E (1251T→G) M 39 (A) (B)
ΔF508/D110H Infertile M 38
ΔF508/L1414S
(4373T→C)
Infertile CBAVD M 44 (A) (B)
ΔF508/V201M, D1270N
& R74W
Infertile CBAVD M 44 (A) [18,19]
2183AA→G/L206W Infertile CBAVD M 40 (A)
711+5G→A/ L206W Infertile CBAVD M 40 (A)identified as CF carriers have higher probabilities of pregnancies
at risk and are therefore offered genetic counselling and prenatal
diagnosis, if a pregnancy is ongoing. Of the 108 couples with
both partners being identified as CF carriers, 89 had a pregnancy
ongoing and prenatal CF screening test was carried out: 20
foetuses (22%) carried no mutations, 47 (53%) carried a
mutation in one of the two CFTR alleles and 22 (25%) carried
mutations on both alleles. Mutations found in the homozygous
(n=2) and heterozygous (n=20) diagnosed foetuses are the
following: ΔF508/ΔF508 (n=1), 711+5G→A/711+5G→A
(n=1), ΔF508/P5L (n=1), 2183AA→G/S42F (n=1), ΔF508/
D1445N (n=1), 711+5G→A/ΔF508 (n=1), G542X/E527G
(n=1), N1303K/1717-1 G→A (n=1), R117H/E527G (n=1),
ΔF508/2183AA→G (n=1), ΔF508/D1152H (n=1), R347H/
ΔF508 (n=1), ΔF508/G542X (n=2), ΔF508/N1303K (n=2),
R1162X/ΔF508 (n=3), N1303K/D1152H (n=3). Further
information with regard to parents' decision following the
results of the prenatal screening is not available.
3.3. CF carrier testing in couples entering medically assisted
reproduction programs
The increasing use of assisted reproduction techniques to
treat infertility has raised concerns about the risk of transmitting
defective genes. For this reason, molecular screening to detect
CFTR mutations is routinely performed before carrying out
assisted reproduction fertilization procedures in couples with
the male partner affected by CBAVD.
We, therefore, evaluated whether the frequency of CFTR
mutations in a sub-group of individuals undergoing MAR (5196
subjects out of the 57,999 screened) was any different from
percentages found in those not needing MAR. A total of 5196
subjects were screened for the presence of CFTR mutations and
frequencies compared to those found in subjects (n=52,803)
not needing MAR. We identified 236 CF carriers within the
Table 3
Frequency of less common CFTR mutations in the general population.
Mutation Frequency Reference
S1235R 1/77 [22,23]
L997F 1/77 [24]
I148T 1/129 [19]
F1052V 1/200 [25]
621+3A→G 1/335 [26]
3601-111 G→C 1/690 [27]
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(4.25%), a value significantly higher (OR=1.48, 95% CI from
1.29 to 1.70, pb0.001) compared to that observed in individuals
not needingMAR (1/32, n=1643). The distribution of mutations
in the identified carriers is shown in Table 1. Among the subjects
tested, 9 resulted to be compound heterozygotes:ΔF508/R117H
(n=3), G542X/D1152H (n=1), R1162X/2789+5G→A (n=1),
R117H/2789 + 5G→A (n = 1), N1303K/D110H (n = 1),
N1303K/D1152H (n= 1), 2789 + 5G→A/R1066H (n= 1)
(Table 2b). The identification of 3 subjects with ΔF508/
R117H confirmed findings from other studies reporting high
frequencies of ΔF508/R117H compound heterozygotes in
males with infertility problems [20,21].
3.4. “Rare”mutations having high frequencies and identification
of new mutations
With the start of population screening tests, mutations
commonly refereed as “rare” and not routinely screened for
have been frequently identified, thus raising the issue of their
involvement as disease-causing mutations. In our study, some ofTable 4
New CFTR mutations found in the general population following 2nd level
analysis.
Aminoacid change Nucleotide change
A349V 1178C→T
D372E 1251T→G
D674V 2153A→T
D806G 2549A→G
I586V 1888A→G
I807V 2551A→G
I840T 2651T→C
L1335F 4135C→T
L1414S 4373T→C
L1480P 4571T→C
M348T 1175T→C
N416S 1379A→G
P1290T 4000C→T
P355S 1195C→T
Q1268R 3935A→G
Q1352E 4186C→G
S431G 2423A→G
S660T 2110T→A
S911R 2865T→G
T1263A 3919A→G
T788I 2495C→T
V920L 2890G→T
Y1381H 4273T→C
Y84H 382T→Cthese mutations were found to have particularly high frequencies
(Table 3). These mutations were previously reported (see
references in Table 3), but their effects on CFTR chloride channel
activity not fully understood. Differently from previous reports,
point mutation I148T was never found in close association with
3199del6 and similarly 3601-111 G→C with 1811+1,2KB
A→G. In addition, DGGE- and/or dHPLC-mediated analysis of
uncertain subjects coupled to DNA sequencing allowed the
identification of 24 new mutations/polymorphisms, which have
never been described before (Table 4).
4. Discussion
After the publication of the guidelines for CF carrier
screening tests in the USA [7,8], Italian CF centres also started
carrying out screening tests for CFTR mutations and providing
newborn screening tests. The underlying hypothesis was that
identification of the causative mutations in the affected child
would allow the parents' mutations to be identified and their
families to benefit by “cascade” family testing. However,
newborn screening tests are unlikely to result in reduced CF
incidence, being the primary aim to diagnose CF at early stages
for the benefit of the affected child. Reduction in CF incidence
could instead be achieved through CF carrier screening tests.
During the last 10 years (1996–2006), we have therefore
screened 57,999 subjects with no history of CF. The aim was to
establish the a priori risk for CF carrier status in the population
analysed and to offer a reliable screening test to couples who
wanted to plan a pregnancy and know their risk to conceive a
CF child. With 1879 CF carriers identified out of 57,999
subjects with no previous history of CF, we estimated an overall
CF carrier frequency of 1:31 (= a priori risk for Italian north-
eastern populations).
Setting up a CF carrier screening has raised important issues.
Firstly, since the risk of carrying CF mutations varies by
ethnicity and because of the large number of CFTR mutations,
currently available screening tests have limitations. With a
limited panel of CFTR mutations, many tests are insufficiently
sensitive particularly in ethnically diverse populations. Recent-
ly, a diagnostic assay based on array primer extension
technology was shown to detect up to 204 different CFTR
mutations [28]. Our test based on a combination of RDB assay
comprising 47 different mutations and DGGE/dHPLC has
demonstrated to be a robust and easily modifiable screening test
for CF carrier status evaluation as well as molecular diagnosis
of affected individuals. Detection rate will surely increase
following the inclusion of new mutations.
A second major issue with CF carrier tests is the identi-
fication of two apparent disease-causing mutations in indivi-
duals not previously diagnosed with CF. The combination of
RDB and DGGE/dHPLC certainly increased the identification
of CF carriers having “rare”/new mutations or polymorphisms.
These are not normally considered disease-causing alterations,
but when associated with more severe mutations, they could
lead to CFTR-related disorders known as “atypical” or “non-
classical” forms of CF. Recently, a study of 335,204 patients
screened for their CF carrier status revealed 4 individuals with
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diagnosed with CF [29]. A likely explanation is that while
severe genetic changes in the 2 CFTR alleles lead to severe
forms of classical CF, other so-called mild mutations can cause
milder or incomplete CFTR-associated phenotypes. While
many of the 1500 different CFTR mutations are known to
cause CF, the status of many missense mutations (around 40%
of all mutations) is extremely difficult to assess, thus raising the
issue of their involvement as disease causing mutations. In
addition, a growing number of complex alleles are thought to
affect the severity of the disease by modulating the effect of a
mutation. The most striking example is the length of the intron
8 polythydimine tract on exon 9 splicing as genetic modifier of
the severity of the R117H mutation. Interestingly, many
missense mutations have been observed at frequencies higher
than expected. In North America, for example, missense
mutations I148T and D1270N were found N100 and N200
times, respectively, more frequently in CF carriers than in
patients. Whether these are real mutations or polymorphisms is
debated, thus emphasizing the need for accurate screening in
order to avoid the presence of second “severe” CFTR gene
alterations. In our study a rare mutation such as S1235R was
found to be moderately frequent (1/77) and despite being
normally classified as “mild”, association with a second CFTR
gene mutation (G542X) can lead to idiopathic chronic
pancreatitis [23]. Similarly, I148T was shown to be associated
with a CF phenotype only when associated with mutation
3199del6 on the same gene [19]. The identification of mild or
“rare”mutations determining variable, or unknown, phenotypes
does therefore represent a serious dilemma for genetic coun-
selling providers, especially in prenatal cases and in couples
planning a pregnancy when both partners carry “rare”/mild
CFTR mutations. With the development of more sophisticated
screening tests, there will be increasing issues associated with
the management of individuals carrying new polymorphisms
and/or “not-disease-causing” mutations.
A clear benefit of CF carrier screening tests is the possibility
to evaluate potential links between CFTR mutations and
malfunctioning male reproductive tracts. As reported by others,
we also found a significantly higher frequency of CF carriers
(1:22 vs 1:32) in subjects enrolled in MAR programmes. The
link between CF and infertility is well documented [30].
Bilateral vessel agenesis is present in nearly 97% of CF males.
CBAVD is also present in 1–2% of the infertile, but otherwise
healthy, male population and accounts for more than 6% of
cases of obstructive azoospermia. Approximately 75–80% of
patients with CBAVD carry mutations in at least one CF allele.
Homozygous CBAVD individuals show one severe and one
mild pathogenic mutation or two mild mutations, but never two
severe mutations. In addition to classic CFTR mutations, up to
40% of CBAVD patients show the 5T allele (5 thymidines
within intron 8), known to reduce CFTR gene splicing
efficiency. In our general population with no history of CF,
11 individuals were found to be compound heterozygote, with 3
having CBAVD and 5 general infertility problems. CBAVD
patients have therefore a chance of 0.5 of transmitting the CF-
causing CFTR mutation to the child (when MAR techniques areused). Assuming a risk of 1/25 of the partner of being a CF
carrier, and when a carrier, again a chance of 0.5 of transmitting
the mutant CFTR gene to the child, the combined risk of
CBAVD couples of having a CF child is 1 in 100 (compared
with a risk of 1/2500 in the control population). Genetic
counselling should therefore be provided to couples with the
male partner having CBAVD and both partners should be tested
for CFTR mutations in order to determine the risk of having a
CF child.
Finally, CF screening tests must have a significant uptake in
the population to lead to a potential reduction in CF incidence.
A measure of the success of our study was the constant increase
of individuals being screened, starting with 1877 (3.2%) in 1996
up to 7453 (12.8% of the total) in 2002. A similar trend was
observed in the sub-group comprising subjects with fertility
problems, as individuals tested raised from 1 (0.1%) in 1996 up
to 1096 (14.7%) in 2002. From 2002 to 2006, the numbers of
test carried out diminished, likely because of others offering
similar tests.
In conclusion, many benefits could be gathered from the set
up of CF carrier screening tests and our findings could also
serve as initial research tools for other CFTR-related diseases.
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